[go: up one dir, main page]

MX2014004354A - Ratones con cadena pesada de inmunoglobulina restringida. - Google Patents

Ratones con cadena pesada de inmunoglobulina restringida.

Info

Publication number
MX2014004354A
MX2014004354A MX2014004354A MX2014004354A MX2014004354A MX 2014004354 A MX2014004354 A MX 2014004354A MX 2014004354 A MX2014004354 A MX 2014004354A MX 2014004354 A MX2014004354 A MX 2014004354A MX 2014004354 A MX2014004354 A MX 2014004354A
Authority
MX
Mexico
Prior art keywords
heavy chain
immunoglobulin heavy
human
gene segments
restricted immunoglobulin
Prior art date
Application number
MX2014004354A
Other languages
English (en)
Other versions
MX355062B (es
Inventor
Andrew J Murphy
Lynn Macdonald
John Mcwhirter
Karolina A Hosiawa
Cagan Gurer
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2014004354A publication Critical patent/MX2014004354A/es
Publication of MX355062B publication Critical patent/MX355062B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporcionan ratones que tienen un locus de cadena pesada de inmunoglobulina restringido, en donde el locus está caracterizado por un segmento del gen VH humano polimórfico único, una pluralidad de segmentos del gen DH humano y una pluralidad de segmentos del gen JH. Se describen métodos para elaborar secuencias de anticuerpo que se unen a un antígeno (por ejemplo, un antígeno viral), que comprende inmunizar a los ratones con un antígeno de interés, en donde el ratón comprende un segmento del gen VH humano único, segmentos del gen DH humano y una pluralidad de segmentos del gen JH, en el locus de cadena pesada de inmunoglobulina endógena.
MX2014004354A 2011-10-17 2012-10-17 Ratones con cadena pesada de inmunoglobulina restringida. MX355062B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161547974P 2011-10-17 2011-10-17
US201261597969P 2012-02-13 2012-02-13
US201261658459P 2012-06-12 2012-06-12
PCT/US2012/060487 WO2013059230A1 (en) 2011-10-17 2012-10-17 Restricted immunoglobulin heavy chain mice

Publications (2)

Publication Number Publication Date
MX2014004354A true MX2014004354A (es) 2014-05-27
MX355062B MX355062B (es) 2018-04-03

Family

ID=47144131

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003739A MX381360B (es) 2011-10-17 2012-10-17 Ratones con cadena pesada de inmunoglobulina restringida.
MX2014004354A MX355062B (es) 2011-10-17 2012-10-17 Ratones con cadena pesada de inmunoglobulina restringida.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003739A MX381360B (es) 2011-10-17 2012-10-17 Ratones con cadena pesada de inmunoglobulina restringida.

Country Status (27)

Country Link
US (5) US10246509B2 (es)
EP (3) EP3216871B1 (es)
JP (6) JP6271435B2 (es)
KR (7) KR20140082824A (es)
CN (3) CN104024418B (es)
AU (4) AU2012326283C1 (es)
BR (1) BR112014008775A8 (es)
CA (1) CA2850534A1 (es)
CY (2) CY1119335T1 (es)
DK (2) DK2627773T3 (es)
ES (2) ES2640139T3 (es)
HR (2) HRP20171357T1 (es)
HU (2) HUE057680T2 (es)
IL (5) IL292030B2 (es)
IN (1) IN2014CN03572A (es)
LT (2) LT3216871T (es)
MX (2) MX381360B (es)
MY (1) MY172946A (es)
PL (2) PL3216871T3 (es)
PT (2) PT2627773T (es)
RS (2) RS56458B1 (es)
RU (2) RU2603090C2 (es)
SG (3) SG10202010120XA (es)
SI (2) SI2627773T1 (es)
SM (2) SMT201700553T1 (es)
WO (1) WO2013059230A1 (es)
ZA (1) ZA201402455B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
AU2010269978B2 (en) 2009-07-08 2016-11-03 Kymab Limited Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PL2501817T5 (pl) 2010-02-08 2021-08-16 Regeneron Pharmaceuticals, Inc. Mysz o wspólnym łańcuchu lekkim
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
CN105753979B (zh) 2010-08-02 2021-05-07 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
SG10201913155QA (en) 2011-02-25 2020-02-27 Regeneron Pharma Adam6 mice
SMT202100357T1 (it) 2011-08-05 2021-07-12 Regeneron Pharma Topi di catena leggera universale umanizzata
DK3311661T3 (da) 2011-09-19 2022-07-11 Kymab Ltd Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20140082824A (ko) * 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
HUE044266T2 (hu) 2011-12-20 2019-10-28 Regeneron Pharma Humanizált könnyûláncú egerek
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
RU2656155C2 (ru) 2012-06-12 2018-05-31 Регенерон Фармасьютикалз, Инк. Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина
KR101764800B1 (ko) 2013-02-20 2017-08-04 리제너론 파마슈티칼스 인코포레이티드 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
SG11201602236SA (en) 2013-10-01 2016-04-28 Kymab Ltd Animal models and therapeutic molecules
EP3096609B1 (en) * 2014-01-24 2021-09-22 Children's Medical Center Corporation High-throughput mouse model for optimizing antibody affinities
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
IL318433A (en) 2014-05-16 2025-03-01 Ablynx Nv Improved immunoglobulin variable complexes
RS63085B1 (sr) 2014-05-16 2022-04-29 Ablynx Nv Varijabilni domeni imunoglobulina
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
IL260526B2 (en) 2016-01-13 2023-10-01 Regeneron Pharma Rodents having an engineered heavy chain diversity region
CA3014208A1 (en) 2016-02-16 2017-08-24 Regeneron Pharamaceuticals, Inc. Non-human animals having a mutant kynureninase gene
RU2745563C2 (ru) 2016-05-20 2021-03-29 Регенерон Фармасьютикалс, Инк. Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
RU2753585C2 (ru) 2016-06-03 2021-08-18 Регенерон Фармасьютикалз, Инк. Животные, не являющиеся человеком, экспрессирующие экзогенную терминальную дезоксинуклеотидилтрансферазу
HRP20250695T1 (hr) 2016-11-04 2025-08-01 Regeneron Pharmaceuticals, Inc. Ne-ljudske životinje koje imaju konstruirani lokus imunoglobulinskog lambda lakog lanca
CN108265035A (zh) * 2016-12-30 2018-07-10 深圳先进技术研究院 一种进化噬菌体宿主特异性的方法
HUE071852T2 (hu) 2017-12-05 2025-09-28 Regeneron Pharma Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
TW202506730A (zh) 2018-03-24 2025-02-16 美商再生元醫藥公司 用於產生抗肽-mhc複合物之治療性抗體的經基因修飾的非人類動物、其製法與用途
CN116420679B (zh) 2018-03-26 2025-10-03 瑞泽恩制药公司 用于测试治疗剂的人源化啮齿动物
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
AU2020289554A1 (en) 2019-06-05 2021-11-18 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
AU2021342159A1 (en) 2020-09-11 2023-03-02 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
EP4051700B1 (en) * 2020-12-23 2025-05-07 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CN118946265A (zh) * 2022-03-21 2024-11-12 百奥赛图(北京)医药科技股份有限公司 具有人源化免疫球蛋白和mhc基因座的经基因修饰的非人动物

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) * 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
CN1203922A (zh) 1997-03-21 1999-01-06 三共株式会社 人源化抗人fas抗体
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
FI105105B (fi) * 1998-02-27 2000-06-15 Finnish Immunotechnology Ltd O Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan
AU5043200A (en) 1999-05-27 2000-12-18 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
NZ524523A (en) 2000-08-03 2006-02-24 Therapeutic Human Polyclonals Production of humanized antibodies in transgenic animals
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
CA2446968C (en) 2001-05-11 2012-07-03 Kirin Beer Kabushiki Kaisha Human artificial chromosome containing human antibody .lambda. light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
CN100480260C (zh) 2002-07-18 2009-04-22 克鲁塞尔荷兰公司 抗体混合物的重组生产
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
AU2004257292A1 (en) 2003-07-15 2005-01-27 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
US20050153392A1 (en) 2003-08-11 2005-07-14 Roland Buelow Transgenesis with humanized immunoglobulin loci
CA2536238C (en) 2003-08-18 2015-04-07 Medimmune, Inc. Humanization of antibodies
RU2251699C1 (ru) 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
WO2005038001A2 (en) 2003-10-14 2005-04-28 Therapeutic Human Polyclonals, Inc. Improved transgenesis by sperm-mediated gene transfer
WO2006029459A1 (en) * 2004-09-13 2006-03-23 Evogenix, Inc Antibodies specific for hepatocellular carcinoma and other carcinomas and uses thereof
JP2008538912A (ja) 2005-04-29 2008-11-13 イナート・ファルマ 遺伝子導入動物および組換え抗体の製造方法
US20090307787A1 (en) 2006-01-25 2009-12-10 Franklin Gerardus Grosveld Generation of heavy-chain only antibodies in transgenic animals
CA2638774C (en) 2006-03-31 2015-11-24 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
HRP20120175T1 (hr) 2006-06-02 2012-03-31 Regeneron Pharmaceuticals Antitijela s visokim afinitetom za humani il-6 receptor
KR102096731B1 (ko) 2007-06-01 2020-04-02 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
WO2009097006A2 (en) * 2007-08-10 2009-08-06 Medarex, Inc. Hco32 and hco27 and related examples
WO2009042589A1 (en) * 2007-09-24 2009-04-02 Vanderbilt University Monoclonal antibodies to respiratory syncytial virus and uses thereof
AU2008335178A1 (en) 2007-12-10 2009-06-18 Ablexis Llc Methods for sequential replacement of targeted region by homologous recombination
WO2009125825A1 (ja) 2008-04-11 2009-10-15 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
US8012714B2 (en) 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
CN102099378B (zh) * 2008-05-16 2016-01-20 埃博灵克斯股份有限公司 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽
EP2288623B1 (en) 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
DK2346994T3 (da) 2008-09-30 2022-02-28 Ablexis Llc Knock-in-mus til fremstilling af kimære antistoffer
CN112690250B (zh) 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
MY164121A (en) * 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
AU2010269978B2 (en) 2009-07-08 2016-11-03 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2595376T3 (es) 2009-12-10 2016-12-29 Regeneron Pharmaceuticals, Inc. Ratones que producen anticuerpos de cadena pesada
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
PL2501817T5 (pl) 2010-02-08 2021-08-16 Regeneron Pharmaceuticals, Inc. Mysz o wspólnym łańcuchu lekkim
CA2802591A1 (en) 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
CN105753979B (zh) 2010-08-02 2021-05-07 瑞泽恩制药公司 制造包含vl结构域的结合蛋白的小鼠
WO2012063048A1 (en) 2010-11-08 2012-05-18 Kymab Limited Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
SG10201913155QA (en) * 2011-02-25 2020-02-27 Regeneron Pharma Adam6 mice
SMT202100357T1 (it) 2011-08-05 2021-07-12 Regeneron Pharma Topi di catena leggera universale umanizzata
DK3311661T3 (da) * 2011-09-19 2022-07-11 Kymab Ltd Manipulation af immunoglobulin-gendiversitet og terapeutiske lægemidler med flere antistoffer
EP3741862A1 (en) 2011-09-19 2020-11-25 Kymab Limited Animals, repertoires & methods for the production of human antibodies
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
KR20140082824A (ko) 2011-10-17 2014-07-02 리제너론 파아마슈티컬스, 인크. 제한된 면역글로불린 중쇄 마우스
GB2496375A (en) 2011-10-28 2013-05-15 Kymab Ltd A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
HUE044266T2 (hu) * 2011-12-20 2019-10-28 Regeneron Pharma Humanizált könnyûláncú egerek
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
WO2013144567A1 (en) 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
RU2656155C2 (ru) * 2012-06-12 2018-05-31 Регенерон Фармасьютикалз, Инк. Гуманизированные не относящиеся к человеку животные с ограниченными локусами тяжелой цепи иммуноглобулина
AU2014214863B2 (en) * 2013-02-06 2019-03-21 Duke University B cell lineage based immunogen design with humanized animals
KR101764800B1 (ko) 2013-02-20 2017-08-04 리제너론 파마슈티칼스 인코포레이티드 변형된 면역글로불린 중쇄 서열을 갖는 비인간 동물
JP6529957B2 (ja) 2013-03-13 2019-06-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 限られた免疫グロブリン軽鎖レパートリーを発現するマウス

Also Published As

Publication number Publication date
RU2016139418A3 (es) 2020-03-20
KR102762747B1 (ko) 2025-02-05
KR20140082824A (ko) 2014-07-02
CN108207807A (zh) 2018-06-29
DK2627773T3 (en) 2017-10-02
RU2603090C2 (ru) 2016-11-20
MX355062B (es) 2018-04-03
SI2627773T1 (sl) 2017-12-29
LT2627773T (lt) 2017-12-27
IL265967A (en) 2019-06-30
EP3216871B1 (en) 2021-12-22
EP2627773A1 (en) 2013-08-21
CN108200885B (zh) 2021-12-14
IL261242A (en) 2018-10-31
AU2020289846A1 (en) 2021-01-28
RU2016139418A (ru) 2018-12-13
US10246509B2 (en) 2019-04-02
JP2016039820A (ja) 2016-03-24
SI3216871T1 (sl) 2022-04-29
IL231819A0 (en) 2014-05-28
HUE057680T2 (hu) 2022-06-28
EP2627773B1 (en) 2017-06-14
SMT201700553T1 (it) 2018-01-11
WO2013059230A1 (en) 2013-04-25
JP2014531909A (ja) 2014-12-04
US9932398B2 (en) 2018-04-03
NZ623102A (en) 2016-09-30
SG11201401181YA (en) 2014-04-28
AU2016204127C1 (en) 2019-02-14
MX381360B (es) 2025-03-12
AU2018203811A1 (en) 2018-06-21
IL292030B2 (en) 2023-07-01
IL282200B (en) 2022-05-01
JP2020202873A (ja) 2020-12-24
AU2012326283B2 (en) 2016-03-17
PT3216871T (pt) 2022-03-15
CN108207807B (zh) 2021-12-31
BR112014008775A2 (pt) 2017-06-13
MY172946A (en) 2019-12-16
US20130323791A1 (en) 2013-12-05
BR112014008775A8 (pt) 2017-09-12
JP2017221223A (ja) 2017-12-21
SMT202200117T1 (it) 2022-05-12
HRP20171357T1 (hr) 2017-12-15
AU2016204127B2 (en) 2018-03-08
JP2019068836A (ja) 2019-05-09
CA2850534A1 (en) 2013-04-25
US20190261612A1 (en) 2019-08-29
RU2743589C2 (ru) 2021-02-20
JP7022803B2 (ja) 2022-02-18
IN2014CN03572A (es) 2015-10-09
KR20210113419A (ko) 2021-09-15
IL292030A (en) 2022-06-01
CY1119335T1 (el) 2018-02-14
CN104024418A (zh) 2014-09-03
PT2627773T (pt) 2017-09-29
US20130096287A1 (en) 2013-04-18
KR20160098514A (ko) 2016-08-18
JP6271435B2 (ja) 2018-01-31
HRP20220253T1 (hr) 2022-04-29
RS62942B1 (sr) 2022-03-31
RU2014118869A (ru) 2015-11-27
JP2022048158A (ja) 2022-03-25
ES2906462T3 (es) 2022-04-18
SG10201602904VA (en) 2016-05-30
KR20250021626A (ko) 2025-02-13
KR20200047786A (ko) 2020-05-07
CN104024418B (zh) 2017-11-07
EP4074833A1 (en) 2022-10-19
ES2640139T3 (es) 2017-10-31
AU2018203811B2 (en) 2020-09-24
HUE034321T2 (en) 2018-02-28
LT3216871T (lt) 2022-03-25
PL2627773T3 (pl) 2017-11-30
IL292030B1 (en) 2023-03-01
US20220177572A1 (en) 2022-06-09
RS56458B1 (sr) 2018-01-31
SG10202010120XA (en) 2020-11-27
AU2012326283C1 (en) 2018-08-23
KR20240006704A (ko) 2024-01-15
PL3216871T3 (pl) 2022-03-21
ZA201402455B (en) 2022-10-26
KR102148683B1 (ko) 2020-08-27
JP6770568B2 (ja) 2020-10-14
AU2016204127A1 (en) 2016-07-14
US20200277371A1 (en) 2020-09-03
KR20190090886A (ko) 2019-08-02
CY1124972T1 (el) 2023-01-05
US11261248B2 (en) 2022-03-01
AU2012326283A1 (en) 2013-05-16
DK3216871T3 (da) 2022-02-21
EP3216871A1 (en) 2017-09-13
CN108200885A (zh) 2018-06-26
IL265967B (en) 2021-04-29
IL282200A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
MY172946A (en) Restricted immunoglobulin heavy chain mice
HK1205873A1 (en) Common light chain mouse
CY1122036T1 (el) Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα
HK1208994A1 (en) Methods for making fully human bispecific antibodies using a common light chain
MX379533B (es) Ratones de cadena ligera universal humanizados.
MX2015012540A (es) Ratón de cadena ligera común.
MX2020010837A (es) Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina.
MY166529A (en) Common light chain mouse
NZ605980A (en) Anti-fap antibodies and methods of use
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ706004A (en) Antibodies for treatment of cancer expressing claudin 6
NZ626269A (en) Anti-phf-tau antibodies and their uses
WO2012135740A3 (en) Cd37-binding molecules and immunoconjugates thereof
SG10201810825YA (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
SG10201908800YA (en) Non-human animals having humanized fc-gamma receptors
NZ710422A (en) Protein combination-based fv library, and preparation method therefor
HK1206283A1 (en) Treatment of multiple sclerosis with anti-cd19 antibody
EP4073123A4 (en) HUMANIZED ANTIBODIES IB ALPHA (GPIBALPHA) ANTIBODIES
WO2013101771A3 (en) Compositions and method for treating autoimmune diseases
EP3336172A4 (en) Method for producing antigen specific monoclonal antibody
MX2021004039A (es) Ratones con cadena pesada de inmunoglobulina restringida.
TH158444A (th) หนูเม้าส์ที่มีโซ่หนักอิมมูโนโกลบูลินเฉพาะ (Restricted immunoglobulin heavy chain mice)
NZ776960A (en) Restricted immunoglobulin heavy chain mice
TH0901002288A (th) การสร้างคลังฟาจที่แสดงแอนติบอดีสายเดี่ยวของมุนษย์แต่ละชนิดบนผิวของฟาจแต่ละอนุภาคและมียีนที่เป็นรหัสของแอนติบอดีนั้นๆ อยู่ในจีโนมของฟาจด้วย (คลังแอนติบอดีของมุนษย์) และการเตรียมแอนติบอดีสายเดี่ยวที่เป็นโปรตีนของมนุษย์ โดยสมบูรณ์ชนิดโมโนโคลนาลและโพลีโคลนาลต่อพิษของงูเห่าไทยด้วยการประยุกต์ใช้คลังฟาจดังกล่าวเป็นเครื่องมือทางชีววิทยา

Legal Events

Date Code Title Description
FG Grant or registration